Alkermes Plc

자세한 내용은 Alkermes Plc 회사

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

회사 정보

종목 코드 ALKS

회사 이름Alkermes Plc

상장일Jul 16, 1991

CEOMr. Richard F. Pops

직원 수1800

유형Ordinary Share

회계 연도 종료Jul 16

주소Connaught House

도시DUBLIN

증권 거래소NASDAQ Global Select Consolidated

국가Ireland

우편 번호D04 C5Y6

전화35317728000

웹사이트https://www.alkermes.com/

종목 코드 ALKS

상장일Jul 16, 1991

CEOMr. Richard F. Pops

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

204.25K

--

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

204.25K

--

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

Other

22.41M

7.31%

데이터 없음

사업별

지역별

사업별USD

이름

수익

비율

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

Other

22.41M

7.31%

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

14.53%

The Vanguard Group, Inc.

11.00%

T. Rowe Price Associates, Inc.

7.04%

State Street Global Advisors (US)

4.86%

RTW Investments L.P.

4.17%

Other

58.40%

주주

비율

BlackRock Institutional Trust Company, N.A.

14.53%

The Vanguard Group, Inc.

11.00%

T. Rowe Price Associates, Inc.

7.04%

State Street Global Advisors (US)

4.86%

RTW Investments L.P.

4.17%

Other

58.40%

주주 유형

주주

비율

Investment Advisor

57.22%

Investment Advisor/Hedge Fund

30.61%

Hedge Fund

12.64%

Research Firm

2.77%

Individual Investor

1.66%

Pension Fund

1.62%

Sovereign Wealth Fund

1.24%

Bank and Trust

0.42%

Private Equity

0.36%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

769

179.19M

108.55%

-26.81M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

2023Q1

604

167.47M

100.88%

-20.36M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

23.98M

14.54%

-541.92K

-2.21%

Mar 31, 2025

The Vanguard Group, Inc.

18.16M

11.01%

-283.51K

-1.54%

Mar 31, 2025

T. Rowe Price Associates, Inc.

11.62M

7.05%

-472.94K

-3.91%

Mar 31, 2025

State Street Global Advisors (US)

8.02M

4.87%

-792.30K

-8.99%

Mar 31, 2025

RTW Investments L.P.

6.88M

4.17%

-673.14K

-8.91%

Mar 31, 2025

Renaissance Technologies LLC

5.74M

3.48%

+260.10K

+4.75%

Mar 31, 2025

Baker Bros. Advisors LP

4.48M

2.72%

+301.53K

+7.21%

Mar 31, 2025

JP Morgan Asset Management

4.13M

2.5%

+3.88M

+1560.15%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.94M

2.39%

+121.05K

+3.17%

Mar 31, 2025

American Century Investment Management, Inc.

3.47M

2.1%

+14.97K

+0.43%

Mar 31, 2025

26.595USD

Alkermes Plc

26.595

개요

회사

금융